Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-15 19:58:26 EDT

PhotosVideosAllPeople
LatestRanked
@monalisarout1701.bsky.socialOct 12, 2026, 5:49 AM

Assessing SSRIs as ICIs adjuvants:
🧠SSRI reduces 2-year mortality by 36% (HR 0.627)
🧪Increases immune-related events by 16% (HR 1.162)
🔬Decreases metastases (HR 0.629)
📊Correlates SLC6A4 with T-cell activity
#ICIs #SSRIs #CancerResearch https://tnyp.me/3bmMl79U/s

Photo, no description
@cancers-mdpi.bsky.socialOct 9, 2026, 7:32 AM

🧩Editor’s Choice

#Immunotherapies for #BreastCancer: From Checkpoint Inhibition to Emerging Cellular Therapies
🧑‍⚕️by Ismini Tsagkaraki, Isaac Gannon et al.
🏥 @royalberkshospital.bsky.social, @uclh.bsky.social
📈6 citations
Link🔗 www.mdpi.com/2072-6694/18...

#TNBC #ICIs #CART #CARNK

Figure 1. Different immunotherapeutic approaches targeting breast cancer. Antibody-based therapies, Tumour Infiltrating Lymphocytes, TCR-Targeting T-cells and CAR-T cell therapies are highlighted here. Advantages and disadvantages of each modality are highlighted with either a green check mark or a red cross respectively. In the middle, the most promising antigenic targets for TCR and CAR-T cell therapies are presented.
@cseb-sceb.bsky.socialOct 1, 2026, 7:45 PM

📢 Webinaire #SCEB & #ICIS !

Les normes de classification au cœur de l’information sur la santé au Canada

📅 14 oct. | 12 h–13 h HE | Zoom
Découvrez la CIM-10-CA, la CCI et le Navigateur des classifications canadiennes de l’ICIS.

🔗 Inscrivez-vous ici: face2faceevents.swoogo.com/csebwebinaro...

Photo, no description
@cancers-mdpi.bsky.socialSep 17, 2026, 10:11 AM

🎯Editor's Choice Paper
#Immunotherapeutic Strategies for #ProstateCancer: A Comprehensive Review
✍️Ana K. Flores-Islas, Cecilia Rico-Fuentes et al.
Find out more🖇️ www.mdpi.com/2072-6694/18...
#PCa #ICIs #mCRPC

Figure 1. PCa tumor immune microenvironment (TIME). An immunosuppressive environment and Immunological ignorance characterize TIME in PCa tumors; some of the most relevant immune cells are effector Treg cells (eTreg), CD8+ T cells, M2 tumor-associated macrophages (TAMs), CD4+ T-cells, and myeloid-derived suppressor cells (MDSCs). Tumor-associated antigens and tumor-specific antigens can be used as diagnostic, prognostic/treatment, or research tools in PCa. PSA: Prostate-specific antigen; PSMA: Prostate-specific membrane antigen; PAP: Prostate acid phosphatase; PSCA: Prostate stem cell antigen; STEAP: Six-transmembrane epithelial antigens of the prostate; PCA3: Prostate cancer antigen 3.